Sign In
Buy DNA
$7.89
-0.110 (-1.38%)
At Close: Jun 12, 2026
4 Small-Cap Value Stocks That Could Go Parabolic
09:30am, Thursday, 16'th May 2024
Small-cap stocks have historically responded positively to interest-rate cuts. These four small-cap equities may be poised for a bull run once the Fed eventually slashes rates.
What's the Difference Between Biotech Stocks and TechBio Stocks?
08:45am, Wednesday, 15'th May 2024
Some high-tech biotechs claim to be "TechBio" companies. The term signals the use of an automation-heavy approach to biotech.
Ginkgo Bioworks to Participate in Two Conferences in May
07:01am, Wednesday, 15'th May 2024
BOSTON , May 15, 2024 /PRNewswire/ -- Ginkgo Bioworks (NYSE: DNA), which is building the leading platform for cell programming and biosecurity, today announced that management will be participating in
Sojitz intends to use its extensive network to help Ginkgo foster business connections within the Japanese bioeconomy TOKYO and BOSTON , May 14, 2024 /PRNewswire/ -- Sojitz, a large Japanese general t
Ginkgo Bioworks Holdings, Inc. (DNA) Q1 2024 Earnings Call Transcript
10:18pm, Thursday, 09'th May 2024
Ginkgo Bioworks Holdings, Inc. (NYSE:DNA ) Q1 2024 Earnings Conference Call May 9, 2024 5:30 PM ET Company Participants Megan LeDuc – Manager-Investor Relations Jason Kelly - Co-Founder & Chief Exec
Ginkgo Bioworks Holdings, Inc. (DNA) Reports Q1 Loss, Lags Revenue Estimates
06:46pm, Thursday, 09'th May 2024
Ginkgo Bioworks Holdings, Inc. (DNA) came out with a quarterly loss of $0.08 per share in line with the Zacks Consensus Estimate. This compares to loss of $0.08 per share a year ago.
Ginkgo Bioworks Reports First Quarter 2024 Financial Results
04:01pm, Thursday, 09'th May 2024
Ginkgo announces several initiatives to accelerate path to Adjusted EBITDA breakeven by end of 2026 Initiatives include a reduction of $200 million in annualized run-rate operating expenses by mid-202
3 Meme Stocks to Sell in May Before They Crash & Burn
01:46pm, Wednesday, 08'th May 2024
The stock market has been on an incredible run over the past year with tech and growth stocks surging. Traders have piled into many fast-moving companies in hopes of locking in quick trading gai
Want $10,000? Invest $1,000 in These 3 Penny Stocks Now
12:31pm, Tuesday, 07'th May 2024
There's the age-old adage, “You have to spend money to make money.” But then again, what if you could spend pennies and get back dollars?
GreenLab Partners with Ginkgo Bioworks to Scale Up Production of Brazzein, a Novel Sweetener
07:01am, Tuesday, 07'th May 2024
To scale up its production of brazzein, GreenLab will leverage its proprietary technology to grow proteins inside corn kernels, optimizing its process with Ginkgo's Plant Trait Services , Protein Serv
Ginkgo Bioworks Announces Presentations at the Upcoming American Society of Gene & Cell Therapy (ASGCT) Annual Meeting
07:01am, Monday, 06'th May 2024
BOSTON , May 6, 2024 /PRNewswire/ -- Ginkgo Bioworks (NYSE: DNA), which is building the leading platform for cell programming and biosecurity, today announced its participation in the 27th American S
Ginkgo Bioworks Announces Date of First Quarter 2024 Results Presentation
07:00am, Thursday, 02'nd May 2024
Presentation and Q&A session scheduled for post-market on Thursday, May 9, 2024 BOSTON , May 2, 2024 /PRNewswire/ -- Ginkgo Bioworks Holdings, Inc. (NYSE: DNA, "Ginkgo"), which is building the leading
Ginkgo Bioworks: Buy, Sell, or Hold?
10:00am, Tuesday, 30'th Apr 2024
Ginkgo Bioworks needs to keep scaling up to increase its efficiency. The challenge is it doesn't have a very long cash runway anymore.
Here's why Cathie Wood's Ginkgo Bioworks (DNA) stock has dived
06:05am, Tuesday, 30'th Apr 2024
Cathie Wood, the founder of Ark Invest, is under intense pressure as most of her ETFs implode. The Ark Innovation Fund (ARKK) ETF has crashed by 72% from its highest level in 2021 while the Ark Genomi
Is a Giant Short Squeeze in Ginkgo Bioworks (DNA) Stock?
05:24pm, Monday, 29'th Apr 2024
Ginkgo Bioworks (NYSE: DNA ) stock has seen a recent surge in short interest combined with a jump in its share price, fueling speculation that a short squeeze is in the makings for DNA stock. Indeed,
